LEAP 2: Oral Lefamulin Demonstrates Favorable Safety, Tolerability for Patients With CABP
April 16th 2019Lefamulin demonstrated non-inferiority when compared with moxifloxacin, and both treatment arms reported a low rate of serious treatment-emergent AEs or treatment-emergent AEs leading to discontinuation.